A company officer sold stock to cover tax liabilities, with no indication of broader insider sentiment.
Travere Therapeutics Chief Commercial Officer sold $101,417 worth of company shares to satisfy tax obligations related to equity awards. The transaction occurred at a pre-set price and volume under a 10b5-1 trading plan.
Prior insider activity at Travere has been limited, with no other recent sales reported by executives or directors. The company’s stock has traded in a narrow range over the past month, reflecting muted investor reaction to pipeline updates.
Shares showed no immediate price movement following the disclosure, remaining flat in after-hours trading.